Aspira Pathlab

{
  "main_header": {
    "sid": 1002885,
    "name": "Aspira Pathlab",
    "stock_name": "Aspira Pathlab",
    "full_name": "Aspira Pathlab & Diagnostics Ltd",
    "name_url": "stocks-analysis/aspira-pathlab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "77.97",
    "chg": 1.74,
    "chgp": "2.28%",
    "dir": 1,
    "prev_price": "76.23",
    "mcapval": "80.25 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540788,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "India SENSEX",
    "isin": "INE500C01017",
    "curr_date": "May 13",
    "curr_time": "",
    "bse_nse_vol": 5219,
    "exc_status": "Active",
    "traded_date": "May 13, 2026",
    "traded_date_str": "2026 05 13",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Caution for Investors",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-valuation-shift-signals-caution-for-investors-3988531",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AspiraPathlabDi_valuationdot_3988531.png",
        "date": "2026-05-13 08:01:42",
        "description": "Aspira Pathlab & Diagnostics Ltd has witnessed a significant re-rating in its valuation parameters, shifting from an attractive to a fair valuation grade despite a robust price rally. This change comes amid a sharp increase in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, prompting investors to reassess the stock’s price attractiveness relative to its historical levels and peer group within the healthcare services sector."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3973225",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AspiraPathlabDi_mojoScore_3973225.png",
        "date": "2026-05-04 10:10:17",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 04 May 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3956606",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AspiraPathlabDi_mojoScore_3956606.png",
        "date": "2026-04-22 10:10:21",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 22 April 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd Falls to 52-Week Low of Rs 49 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aspira-pathlab-diagnostics-ltd-falls-to-52-week-low-of-rs49-3947617",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AspiraPathlabDi_priceRelatedfactors_3947617.png",
        "date": "2026-04-15 12:10:15",
        "description": "A sharp decline in Aspira Pathlab & Diagnostics Ltd has pushed the stock to a fresh 52-week low of Rs 49 on 15 Apr 2026, marking a significant 39.5% drop from its 52-week high of Rs 81. This comes amid heightened volatility and a continuation of recent losses, despite some contrasting financial signals."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-ltd-is-rated-strong-sell-3941524",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/AspiraPathlabDi_mojoScore_3941524.png",
        "date": "2026-04-10 10:10:24",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 10 April 2026, providing investors with an up-to-date view of the company’s position."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3923830",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3923830.png",
        "date": "2026-03-30 10:10:17",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3893330",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3893330.png",
        "date": "2026-03-16 10:10:02",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-strong-sell-3873246",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/AspiraPathlabDi_mojoScore_3873246.png",
        "date": "2026-03-05 10:10:02",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Downgraded to Strong Sell Amid Financial and Technical Weakness",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-strong-sell-amid-financial-and-technical-weakness-3841909",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_mojoScore_3841909.png",
        "date": "2026-02-16 08:38:03",
        "description": "Aspira Pathlab & Diagnostics Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, technical indicators, and overall quality. The downgrade reflects significant deterioration in quarterly earnings, a shift in technical trends, and a reassessment of valuation attractiveness, signalling heightened caution for investors in the healthcare services sector."
      }
    ],
    "total": 6143,
    "sid": "1002885",
    "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885"
  },
  "announcements": [
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "15-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Aspira Pathlab & Diagnostics Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85100MH1973PLC289209</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Company is under the process to appoint Company Secretary <br/> Designation: Company Secretary <br/> EmailId: info@aspiradiagnostics.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Balkrishna Talawadekar <br/> Designation: Chief Financial Officer <br/> EmailId: balkrishna.talawadekar@aspiradiagnostics.com</div> </div> <div> <br/> Date: 15/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    },
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "15-Apr-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Aspira Pathlab & Diagnostics Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85100MH1973PLC289209</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>NA</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>NA</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Company is under the process to appoint Company Secretary</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Balkrishna Talawadekar </td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 15/04/2026<br/><br/></div>",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "14-Apr-2026",
      "details": "Compliance Certificate in accordance with Regulation 74(5) of SEBI (DP) Regulations 2018 For quarter ended 31 March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aspira Pathlab & Diagnostics Ltd: Valuation Shift Signals Caution for Investors

2026-05-13 08:01:42

Aspira Pathlab & Diagnostics Ltd has witnessed a significant re-rating in its valuation parameters, shifting from an attractive to a fair valuation grade despite a robust price rally. This change comes amid a sharp increase in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios, prompting investors to reassess the stock’s price attractiveness relative to its historical levels and peer group within the healthcare services sector.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-05-04 10:10:17

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 04 May 2026, providing investors with the latest insights into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-04-22 10:10:21

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 22 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd Falls to 52-Week Low of Rs 49 as Sell-Off Deepens

2026-04-15 12:10:15

A sharp decline in Aspira Pathlab & Diagnostics Ltd has pushed the stock to a fresh 52-week low of Rs 49 on 15 Apr 2026, marking a significant 39.5% drop from its 52-week high of Rs 81. This comes amid heightened volatility and a continuation of recent losses, despite some contrasting financial signals.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-04-10 10:10:24

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Feb 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 10 April 2026, providing investors with an up-to-date view of the company’s position.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-03-30 10:10:17

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026, reflecting a shift from the previous 'Sell' grade. However, the analysis and financial metrics discussed here represent the company’s current position as of 30 March 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-03-16 10:10:02

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Strong Sell

2026-03-05 10:10:02

Aspira Pathlab & Diagnostics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 February 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Downgraded to Strong Sell Amid Financial and Technical Weakness

2026-02-16 08:38:03

Aspira Pathlab & Diagnostics Ltd has been downgraded from a Sell to a Strong Sell rating following a comprehensive reassessment of its financial performance, valuation metrics, technical indicators, and overall quality. The downgrade reflects significant deterioration in quarterly earnings, a shift in technical trends, and a reassessment of valuation attractiveness, signalling heightened caution for investors in the healthcare services sector.

Read full news article

View All News